🔴 British Dragon

Stanabol (Stanozolol)

✔️ Substance: Stanozolol
✔️ Price For: 100 tabs (10 mg/tab)
✔️ Brand: British Dragon

Shipping :

International

U.S. Domestic

Out of stock

British Dragon Pharma Stanabol 10 mg

IDENTITYCompoundStanozolol
BrandBritish Dragon Pharma
Strength10 mg/tab
FormOral Tablet
ClassDHT-Derivative AAS

PHARMACOLOGYRouteOral
17α-AlkylatedYes
AromatizationNone
TargetAndrogen Receptor
Hepatic RiskSignificant

SAFETYHPTA SuppressionPossible
Liver RiskHigh
Lipid ImpactAdverse
EstrogenNo Conversion
MonitoringImportant

STORAGE & PACKAGEBrandBritish Dragon Pharma
Package100 Tabs
Strength10 mg/tab
StorageFollow Label
Protect FromHeat & Moisture

DOSING INFORMATIONClinical DoseIndication-Specific
Bodybuilding DoseNot Established
AdministrationOral (Tablet)
FrequencyPrescription-Dependent
Usage PeriodNo Validated AAS Cycle

USAGE PROFILEUsageClinical / Non-Medical
AdministrationOral
TimingIndication-Specific
DurationClinically Defined
BodybuildingNot Approved

RECOVERYPCTNo Standard Protocol
SuppressionPossible
RecoveryIndividual
HormonesClinical Assessment
Follow-UpLaboratory Monitoring

STACKINGBulkingRisk Increases With AAS
CuttingNon-Medical Use Reported
Lean MassNon-Medical Use Reported
BeginnerNo Risk-Free Stack
SupportMedical Monitoring

MECHANISM OF ACTIONTargetAndrogen Receptor
ActionAR Activation
SignalingGene Transcription
AnabolicProtein Synthesis
EstrogenNo Aromatization

PHARMACOKINETICSAbsorptionOral
Half-LifeVariable by Study
MetabolismHepatic
MetabolitesHydroxylated
ExcretionUrinary Metabolites

CONTRAINDICATIONSPregnancyContraindicated
Liver DiseaseMajor Concern
ProstateAssessment Needed
LipidsMonitor
CardiacRisk Assessment

COMPARISONSStanozololOral DHT Derivative
OxandroloneOral AAS
MethenoloneDHT-Derivative AAS
TestosteroneAromatizable AAS
Key Point17α-Alkylated Oral Profile

CHEMICAL PROFILEFormulaC21H32N2O
Weight328.50 g/mol
CAS10418-03-8
ClassAnabolic-Androgenic Steroid
StructurePyrazole Steroid

WHO IT'S FOR

Stanozolol is an anabolic-androgenic steroid with established pharmacology and historical clinical use for specific medical indications. Bodybuilding and athletic performance enhancement are not approved indications. Product information should therefore be interpreted as educational pharmacology rather than a recommendation for non-medical use.

BODYBUILDING USAGE

Commonly discussed as an oral AAS
Does not aromatize to estradiol
Androgen-receptor activity may influence anabolic signaling
17α-alkylation permits oral activity
17α-alkylation is also associated with hepatic risk
May suppress endogenous testosterone production
No medically validated bodybuilding cycle or PCT exists

WHAT IS BRITISH DRAGON?

British Dragon Pharma is the brand specified for this Stanabol product. Brand identification alone does not establish pharmaceutical authenticity, potency, quality or regulatory approval. Packaging, batch information, product provenance and applicable regulatory status should be independently verified.

WHY CHOOSE BRITISH DRAGON?

For an objective product assessment, relevant considerations include verified identity, stated 10 mg tablet strength, packaging integrity, batch traceability and regulatory status. Brand claims should not replace independent quality verification, particularly for products distributed outside regulated pharmaceutical channels.

BENEFITS

Androgen-receptor activity
Oral bioavailability
No aromatization
Anabolic signaling
Documented pharmacological activity
Clinical history for selected indications

POTENTIAL SIDE EFFECTS

Cholestatic liver injury
Adverse lipid changes
HPTA suppression
Acne and oily skin
Androgenic hair effects
Virilization in females
Blood pressure changes
Potential cardiovascular risk

PERFORMANCE PROFILE

Anabolic Activity

80%

Androgenic Activity

65%

Hepatic Concern

85%

Lipid Concern

80%

Aromatization

OVERVIEW

Stanabol contains stanozolol, a synthetic anabolic-androgenic steroid structurally related to dihydrotestosterone. Stanozolol contains a pyrazole ring and a 17α-methyl modification that contributes to its oral activity. It acts through the intracellular androgen receptor and does not aromatize to estradiol.

The oral pharmacology of stanozolol is closely associated with its 17α-alkylated structure. This modification can permit oral administration but is also relevant to hepatic safety. NCBI LiverTox identifies stanozolol among androgenic steroids associated with cholestatic liver injury.

CONCLUSION

British Dragon Pharma Stanabol 10 mg is identified as an oral stanozolol formulation supplied as 10 mg tablets. Stanozolol is a DHT-derived anabolic-androgenic steroid with activity at the androgen receptor and no conversion to estradiol through aromatization.

The compound's 17α-alkylated structure is an important pharmacological characteristic. It supports oral activity but is also associated with clinically significant hepatic concerns. NCBI LiverTox documents cholestatic liver injury associated with anabolic-androgenic steroids including stanozolol.

There is no evidence-based bodybuilding dosage in mg/week, cycle duration or standardized PCT protocol that can be presented as medically established. Clinical administration is indication-specific. Non-medical use may involve hepatic, cardiovascular, lipid and endocrine risks, making appropriate medical evaluation and laboratory monitoring important.

Disclaimer

This content is provided exclusively for educational and informational purposes. It does not constitute medical advice, treatment recommendations or endorsement of non-medical anabolic steroid use. Bodybuilding use of stanozolol is not an approved therapeutic indication. Readers should consult qualified healthcare professionals regarding medical questions, laboratory monitoring, adverse effects and applicable laws in their jurisdiction.